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Abstract 
Introduction: Current succesful AGC (Accurate Glycemic Control) protocols require extra 
clinical effort and are impractical in less acute wards where patients are still susceptible to 
stress-induced hyperglycemia. Long-acting insulin Glargine has the potential to be used in a 
low effort controller. However, potential variability in efficacy and length of action, prevent 
direct in-hospital use in an AGC framework for less acute wards. 
Method: Clinically validated virtual trials based on data from stable ICU patients from the 
SPRINT cohort who would be transferred to such an approach are used to develop a 24-hour 
AGC protocol robust to different Glargine potencies (1.0x, 1.5x and 2.0x regular insulin) and 
initial dose sizes (dose = total insulin over prior 12, 18 and 24 hours). Glycemic control in 
this period is provided only by varying nutritional inputs. Performance is assessed as %BG in 
the 4.0-8.0mmol/L band and safety by %BG<4.0mmol/L.  
Results: The final protocol consisted of Glargine bolus size equal to insulin over the previous 
18 hours. Compared to SPRINT there was a 6.9% - 9.5% absolute decrease in mild 
hypoglycemia (%BG<4.0mmol/L) and up to a 6.2% increase in %BG between 4.0 and 
8.0mmol/L. When the efficacy is known (1.5x assumed) there were reductions of: 27% BG 
measurements, 59% insulin boluses, 67% nutrition changes, and 6.3% absolute in mild 
hypoglycemia.  
Conclusion: A robust 24-48 clinical trial has been designed to safely investigate the efficacy 
and kinetics of Glargine as a first step towards developing a Glargine-based protocol for less 
acute wards. Ensuring robustness to variability in Glargine efficacy significantly affects the 
performance and safety that can be obtained. 
  
1.0 Introduction 
 
Critically ill patients often suffer stress induced hyperglycemia [1]. Hyperglycemia is 
associated with an increased risk of infection, myocardial infarction and mortality [2-4]. 
Attempting to control hyperglycemia can significantly increase the risk of hypoglycemia [5] 
making original promising results [6, 7] difficult to repeat [8-10]. The SPRINT glycemic 
control protocol [7] is the only published protocol to reduce both mortality and 
hypoglycemia. However, it requires BG measurements every 1 – 2 hours. Thus, the clinical 
effort required is high and may not be necessary for all patients. 
 
It is common for patients to be admitted to a High Dependency Unit (HDU) if they are not 
intubated or do not require extensive circulatory support. There can be a reluctance to use 
AGC (Accurate Glycemic Control) protocols in the HDU due to the clinical effort and 
relatively limited nursing resources [11], leading to a tolerance of some hyperglycemia. 
However, these patients are still susceptible to counter-regulatory stress responses and 
hyperglycemia, necessitating an effective method to transition glycemic control from critical 
care to less acute wards with less nursing resources and less use of intravenous lines to 
deliver insulin or other drugs. 
 
Glargine is a very long acting insulin analogue used to manage Type 1 diabetes, primarily in 
relatively low doses (per hour) to replace basal insulin. It is administered subcutaneously and 
released very slowly into the blood plasma over 22 – 26 hours [12]. Hence, it has potential 
advantages for a low intensity AGC protocol requiring only one daily administration. 
 
Although many studies have been carried out on the specific kinetics and dynamics of 
Glargine in healthy individuals, there is still insufficient data for use with in-hospital AGC 
protocols on highly dynamic, critically ill patients. Current studies indicate that Glargine may 
be up to twice as potent as regular insulin [13], which, with varying kinetics and appearance 
rates [14], could add significant risk in using higher doses for these patients whose insulin 
sensitivity can vary significantly over time compared to healthy individuals [15].  
 
Further clinical information about the dynamics of Glargine in these patients is required to 
avoid unnecessary risk. Model-based control and simulation environments can be used to 
develop clinical protocols to safely examine different expected action profiles and efficacy of 
Glargine in these patients, while simultaneously providing AGC. In particular, this study 
develops a first model-based controller to be used in 24 hour pilot trials to assess the potential 
of Glargine in this cohort, and to also collect data on the issues of efficacy and kinetics while 
producing safe, effective AGC in a replicable fashion. This is the first example to employ 
model-based control to elucidate specific drug properties. 
  
2.0 Methods: 
The SING (Stochastic Insulin Nutrition and Glargine) controller was developed using 
clinically validated virtual trials [16] on virtual patients based on retrospective clinical data. It 
combines the ICING (Intensive Control Insulin Nutrition Glucose) model [17] of insulin-
glucose pharmacokinetics and pharmacodynamics and glucose disappearance in plasma with 
a validated model of subcutaneous pharmacokinetics of Glargine from injection to 
appearance in plasma [18-20] and makes use of the stochastic forecasting used in STAR [21]. 
 
2.1 ICING Model: 
Five differential equations describe the glucose-insulin pharmacokinetics and 
pharmacodynamics in the plasma and interstitium with one state-dependent function: 
 
?̇? =  −𝒑𝑮𝑮(𝒕) −  𝑺𝑰𝑮(𝒕) 𝑸(𝒕)𝟏 +  𝜶𝑮𝑸(𝒕) + 𝐦𝐢𝐧(𝒅𝟐𝑷𝟐,𝑷𝒎𝒂𝒙) +  𝑬𝑮𝑷𝒃 − 𝑪𝑵𝑺 + 𝑷𝑵(𝒕)𝑽𝒈   (𝟏) 
?̇? =  −  𝒏𝑳𝑰(𝒕)
𝟏 + 𝜶𝑰𝑰(𝒕) − 𝒏𝑲𝑰(𝒕) − 𝒏𝑰�𝑰(𝒕) − 𝑸(𝒕)� +  𝒖𝒆𝒙(𝒕)𝑽𝑰 + (𝟏 − 𝒙𝑳)𝒖𝒆𝒏(𝑮)𝑽𝑰     (𝟐) 
?̇? =  𝒏𝑰�𝑰(𝒕) − 𝑸(𝒕)� −  𝒏𝑪 𝑸(𝒕)𝟏 +  𝜶𝑮𝑸(𝒕)                                        (𝟑) 
?̇?𝟏 =  −𝒅𝟏𝑷𝟏 + 𝑷(𝒕)                                                        (4) 
?̇?𝟐 =  −𝐦𝐢𝐧(𝒅𝟐𝑷𝟐,𝑷𝒎𝒂𝒙) + 𝒅𝟏𝑷𝟏                                               (𝟓) 
𝒖𝒆𝒏(𝑮) =  𝐦𝐚𝐱�𝟏𝟔.𝟔𝟕, 𝟏𝟒𝑮(𝒕)𝟏 + 𝟎.𝟎𝟏𝟒𝟕𝑮(𝒕) − 𝟒𝟏�                             (𝟔) 
 
Where G(t) [mmol/L] is the total plasma glucose, I(t) [mU/L] is the plasma insulin and 
interstitial insulin is represented by Q(t) [mU/L]. Exogenous insulin input is represented by 
uex(t) [mU/min] and endogenous insulin production is estimated with uen [mU/min], modelled 
as a function of plasma glucose concentration determined from critical care patients with a 
minimum pancreatic output of 1U/hr. P1 [mmol] represents the glucose in the stomach and P2 
[mmol] represents glucose in the gut. Enteral glucose input is denoted P(t) [mmol/min]. 
Table 1 shows the major components and constants of the model defined in Equations 1-5. A 
graphical overview is presented in Figure 1. 
Table 1: Constants and identified parameter ranges in the ICING model of Equations 1 – 6 
Model 
variable 
Numerical value (or typical 
range) 
Definition 
Gp  
0.006 min-1 endogenous glucose clearance 
IS  [1x10
-7 – 1x10-2] L/(mU.min)  insulin sensitivity 
Gα  
1/65 L/mU saturation of insulin-dependent glucose clearance and receptor-
bound insulin clearance from interstitium 
1d  -ln(0.5)/20 rate of glucose transfer between the stomach and gut 
2d  -ln(0.5)/100 rate of glucose transfer from the gut to the bloodstream 
bEGP  
1.16 mmol/min typically Basal endogenous glucose production (unsuppressed by glucose 
and insulin concentration) 
CNS  0.3 mmol/min non-insulin mediated glucose uptake by the central nervous 
system 
GV  
13.3 L glucose distribution volume 
maxP  
6.11 mmol/min Maximum disposal rate from the gut 
𝑛𝐼 ,𝑛𝑐 0.0075 min-1 rate of transport between plasma and interstitial insulin 
compartments 
Iα  1.7x10
-3 L/mU saturation of plasma insulin clearance by the liver 
IV  4.0 L insulin distribution volume 
xL 0.67 First-pass hepatic insulin clearance 
nK 0.0542 min-1 clearance of insulin from plasma via the renal route 
nL 0.1578 min-1 clearance of insulin from plasma via the hepatic route 
 Figure 1: ICING model schematic overview 
2.2 Glargine Compartment Model 
The Glargine Compartment model captures the kinetics of Glargine from injection to 
appearance in plasma. Glargine has four states: precipitate, hexameric, monomeric / dimeric, 
and local interstitium. Figure 2 shows the interaction of these states [18, 19]. The resulting 
compartment model is defined: 
Precipitate State 
     ?̇?𝑔𝑙𝑎(𝑡) = −𝑘𝑝𝑟𝑒𝑝,𝑔𝑙𝑎𝑝𝑔𝑙𝑎(𝑡)1 + 𝑘𝑝𝑟𝑒𝑝,𝑔𝑙𝑎𝑟𝑑𝑖𝑠,𝑚𝑎𝑥 𝑝𝑔𝑙𝑎(𝑡) +    𝑢𝑝,𝑔𝑙𝑎(𝑡)                             (7) 
𝒖𝒑,𝒈𝒍𝒂(𝒕) =  𝜶𝒈𝒍𝒂𝒖𝒕𝒐𝒕𝒂𝒍,𝒈𝒍𝒂(𝒕)                                           (8) 
Hexameric State 
?̇?𝒉,𝒈𝒍𝒂(𝒕) =  −�𝒌𝟏,𝒈𝒍𝒂 + 𝒌𝒅�𝒙𝒉,𝒈𝒍𝒂(𝒕) + 𝒌𝒑𝒓𝒆𝒑,𝒈𝒍𝒂𝒑𝒈𝒍𝒂(𝒕)
𝟏+
𝒌𝒑𝒓𝒆𝒑,𝒈𝒍𝒂
𝒓𝒅𝒊𝒔,𝒎𝒂𝒙 𝒑𝒈𝒍𝒂(𝒕)                     (9) 
𝒖𝒉,𝒈𝒍𝒂(𝒕) =  𝒖𝒕𝒐𝒕𝒂𝒍,𝒈𝒍𝒂(𝒕)�𝟏 − 𝜶𝒈𝒍𝒂� −  𝒖𝒎,𝒈𝒍𝒂(𝒕)                                (10) 
Dimeric/Monomeric State 
?̇?𝒅𝒎(𝒕) =  −(𝒌𝟐 + 𝒌𝒅)𝒙𝒅𝒎(𝒕) + 𝒌𝟏,𝒈𝒍𝒂𝒙𝒉,𝒈𝒍𝒂(𝒕) + 𝒖𝒎,𝒈𝒍𝒂(𝒕)                      (11) 
Interstitium 
?̇?𝒊(𝒕) =  −(𝒌𝟑 + 𝒌𝒅𝒊)𝒙𝒊(𝒕) + 𝒌𝟐𝒙𝒅𝒎(𝒕)                                       (12) 
Where pgla(t) [mU] is the total Glargine in precipitate form, xh,gla(t) [mU] is the total Glargine 
in hexameric form, xdm(t) [mU] is the total Glargine in monomeric / dimeric form and xi(t) 
[mU] is the total Glargine in the (local) interstitium. The exogenous Glargine is represented 
by up,gla(t) [mU] in the precipitate form, um,gla(t) in the monomeric / dimeric form and uh,gla(t) 
in the hexameric form. All other terms and values are defined in Table 2, based on an 
extensive validation study [18, 19]. 
 
 
Figure 2: Glargine Compartment Model Overview 
 
Table 2: Constants and definitions in the Glargine compartment model 
Model 
Variable Numerical Value Description 
kprep,gla 0.0216 [min-1] Glargine precipitate dissolution rate 
alphagla 0.9462 
 
Fraction of glargine as precipitate 
k1,gla 0.0062 [min-1] Hexamer dissociation rate 
D 9.00x10-5  [cm2/min] Diffusion constant for hexameric and dimeric/monomeric states 
k2 0.0106 [min-1] Dimeric/monomeric insulin transport rate into interstitium 
k3 0.0618 [min-1] Interstitium transport rate into plasma 
kdi 0.029 [min-1] Rate of loss from interstitium 
Vx 11.38 [L] Subcutaneous insulin distribution volume 
Br_dismax 2.3134 [mU/min] Baseline glargine precipitate dissolution rate 
QD 1.50x10-2 [ml2/mU2] Hexameric–dimeric equilibrium constant 
Utres 2.01x103 [mU] Dosage threshold 
 
Glargine release from precipitate to hexameric form is a saturable process. The maximum 
dissolution rate, rdis,max [mU/min], gives Glargine its unique kinetic profile and is defined: 
𝒓𝒅𝒊𝒔,𝒎𝒂𝒙 = 𝑩𝒓𝒅𝒊𝒔,𝒎𝒂𝒙�𝜶𝒈𝒍𝒂𝒖𝒕𝒐𝒕𝒂𝒍,𝒈𝒍𝒂 < 𝑼𝒕𝒓𝒆𝒔� + 𝑩𝒓𝒅𝒊𝒔,𝒎𝒂𝒙𝜶𝒈𝒍𝒂𝒖𝒕𝒐𝒕𝒂𝒍,𝒈𝒍𝒂𝑼𝒕𝒓𝒆𝒔 �𝜶𝒈𝒍𝒂𝒖𝒕𝒐𝒕𝒂𝒍,𝒈𝒍𝒂 ≥ 𝑼𝒕𝒓𝒆𝒔�   (13) 
where 𝐵𝑟𝑑𝑖𝑠,𝑚𝑎𝑥 [mU/min] is the baseline precipitate dissolution rate and 𝑈𝑡𝑟𝑒𝑠  [mU] is the 
dosage threshold. The volume of the Glargine injected also has an effect on the kinetics in the 
form of a diffusive loss from the hexameric and monomeric /dimeric states. The rate of this 
diffusive loss kd [min-1] is defined: 
𝒌𝒅 = 𝟑𝑫𝒓                                                                       (14) 
𝒓 = �𝟑𝑽𝒊𝒏𝒋
𝟒𝝅
�
𝟏/𝟑                                                                (15) 
 
where r [cm] is the radius of the depot formed by the subcutaneous injection and D [cm2/min] 
is the diffusion constant for the hexameric and monomeric /dimeric states.  
Finally the initial quantity of the Dimeric/Monomeric state in solution is found by solving the 
following derived from [19]: 
𝑸𝑫𝑽𝒊𝒏𝒋 �
𝑼𝒎
𝑽𝒊𝒏𝒋
�
𝟑 + 𝒖𝒎 − 𝒖𝒕𝒐𝒕𝒂𝒍�𝟏 − 𝜶𝒈𝒍𝒂� = 𝟎                             (16) 
 
2.3 Control Approach 
The main goal is to develop a robust and safe controller to investigate the efficacy and 
variability in Glargine kinetics, without degrading control quality or safety from 
hypoglycemia. The main issues are the potential variation in Glargine efficacy (1.0-2.0x), the 
periods of low insulin appearance at the start and end of Glargine’s 22-26 hour action period, 
and the need to modulate nutrition rates during Glargine administration for safety and 
performance because insulin administration is determined solely by Glargine appearance. 
 
There is evidence suggesting that Glargine may be to be up to 2 times as effective as regular 
insulin, partly attributed to a more effective bonding to the IGF-I receptor [22]. Hence, this 
study assumes an estimated Glargine efficacy factor of 1.5 for design, in the absence of other 
data. Each resulting controller was then tested with efficacy factors of 1.0, 1.5 and 2.0. If a 
controller provided a satisfactory level of control for all three efficacies then it was deemed 
safe and robust to this variable. 
 
Although Glargine has a relatively flat action profile that acts over a 22-26 hour period [23], 
3-6 hours is required before a significant appearance of insulin is observed in plasma, 
resulting in a period of low insulin appearance immediately after Glargine is administered. A 
similar phenomenon occurs at the end of the 22-26 hour period. For this trial design, the 
STAR protocol [21] is assumed running during the first and last 4 or 6 hours of the estimated 
24-hour period after Glargine is administered to supplement Glargine appearance with IV 
insulin, as it is the current standard of care in Christchurch Hospital.  
 
To best observe the effects of Glargine, a period of Glargine as the only exogenous insulin is 
desired to eliminate other factors. However, longer periods increase the potential for control 
degradation. During the 16-hour peak of Glargine action, no exogenous insulin is 
administered, during which glycemic control is achieved only by modulating nutrition 
administration rates. The results will allow determination of Glargine efficacy and kinetics 
for each patient, and thus their variability across a test cohort.  
 
BG measurements are intended to be taken hourly during the 24-hour trials to ensure safety. 
However, for in-silico virtual trials, 2 and 3-hourly BG measurements are used for the 
Glargine isolation period to illustrate the potential to reduce clinical effort.  
 
Glargine bolus size was based on the total insulin previously administered to the patient, as a 
simple and easily calculated bedside metric. The sum over the previous 12, 18 and 24 hours 
before the Glargine is administered was tested. Values less than the 24-hour sum reflect both 
safety concerns over efficacy, as well as the tendency for stable patients to improve and 
require increasingly less insulin  [15]. 
 
STAR [21] targets a forecasted 5th and 95th percentile glucose values to specified BG ranges. 
During the 16 hour Glargine isolation period this BG target places the 95th percentile BG 
outcome on 8 mmol/L, otherwise the 5th is placed on 4.4mmol/L. Figure 3 illustrates the 
stochastic bands used by STAR when recommending treatments. A, B, and C show the 5th 
percentile of BG values for a given intervention and D, E, and F show the 95th percentile BG 
value, for 1, 2 and 3-hourly predictions.  
 
The lower BG target is 4.4 mmol/L with an upper tolerance of 1mmol/L when a 5th percentile 
BG outcome to low bound target is used. The upper BG target is 8.0 mmol/L with an upper 
tolerance of 1mmol/L when a 95th percentile BG outcome to high bound target is used in the 
Glargine isolation period. The tight control achieved with SPRINT (the standard protocol in 
the Christchurch ICU) is not expected with the SING controller due to the decreased 
interventions in the Glargine isolation period. Therefore, the large tolerance bands are chosen 
to ensure higher nutrition rates and loosen regulation for these less acute, stable wards. 
 
Figure 3: Schematic of control using stochastic forecasting showing a typical BG profile and 1-3 hour 
forecast BG bands. Target range of 4.4-8.0 mmol/L is shown with the 1mmol/L tolerances used in the 
different controllers. 
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The controller logic for targeting the 95th percentile BG outcome is shown in Figure 4. It 
calculates the patient outcomes for nutrition at the highest allowed nutrition rate and attempts 
to target the 95th percentile of BG outcomes to the upper target band. A check is made to 
ensure that the 5th percentile of BG outcomes does not drop below the lower band. If an 
acceptable treatment is not found, the nutrition rate is reduced and the logic re-applied. For 
the in-silico virtual trials, 2 and 3 hourly measurements are permitted by running the logic in 
Figure 4 with 1, 2 and 3-hourly forecasts.  Note that only nutrition can be modulated in this 
period to control glycemia once Glargine is given. Similar logic is used for the 5th percentile 
controller. 
 
Figure 4: Controller logic. It modulates nutrition only and assumes insulin appearance based on the 
models of Equations 1-6 and 7-16 
The clinical trial design consists of: 
• Glargine administered based on patient’s previous insulin requirements 
• STAR recommended insulin boluses administered on top of the Glargine at the start 
and end of the action profile. The 5th percentile BG outcome to low bound target is 
used in this period. 
• No exogenous IV insulin is recommended during the 16-hour peak Glargine 
appearance, 95th percentile BG outcome to high bound target is used. 
• BG measurements hourly for safety 
Finally, a second controller, SING2, is designed specifically to demonstrate the potential 
reductions in effort if the efficacy of Glargine is known so that a more aggressive and lower 
clinical effort control method can be implemented safely. The SING2 controller’s logic in 
this specific case is defined: 
• Assumes Glargine efficacy of 1.5x 
• Glargine bolus size equal to the insulin administered over the previous 24 hours 
• STAR recommended boluses on top of Glargine for all 24-hours 
•  2 and 3 hourly treatments permitted per STAR [21] 
• 95th percentile BG outcome is targeted to the high bound 
• The upper tolerance band on the upper target is 1 mmol/L 
 
2.4 Virtual Trials 
 
Clinically validated virtual trials [16] were run on virtual patients made from retrospective 
clinical data. The virtual patients were created using the clinical data to create hourly insulin 
sensitivity profiles which are used to simulate the effects of different treatments on the 
patients. 
 
The following virtual trials were run on the virtual patient cohort. Simulation outcomes for 
the 24 hour trials were used to verify performance both directly against SPRINT. 
• Glargine bolus size equal to total insulin recommendations over the previous 12, 18 
and 24 hours. Each run at 1.0, 1.5 and 2.0x efficacy with 95th BG outcome targeted to 
the high bound during a Glargine isolation period of 16 hours 
• Best performing Glargine bolus size with a Glargine isolation period of 12 hours at 
1.0, 1.5 and 2.0x efficacy with 95th BG percentile to high bound targeting during the 
isolation period 
• Best performing controller logic with 5th BG percentile to low bound targeting 
throughout 
• Glargine bolus size equal to total insulin recommendations over the previous 12, 18 
and 24 hours at 1.5 efficacy with no Glargine isolation period and 95th BG percentile 
to high bound targeting throughout 
The outcomes are used to determine the most robust and safest dose and control response. 
 
2.5 Performance Metrics 
Results from the clinically validated in-silico virtual trials are compared to the original 
SPRINT clinical data to assess safety and performance. An overall increase in BG levels is 
expected as a result of decreased clinical intervention without increasing the risk of 
hypoglycemia. The performance of each controller was assessed by the following criteria: 
1. Effort: Number of nursing interventions from nutrition rate changes, insulin boluses 
and BG measurements 
2. Performance: Measuring the percentage of BG between 4.0 and 8.0 mmol/L 
3. Nutrition: Enteral nutrition administration rates as a percentage of ACCP/SCCM 
goal rates [24] 
4. Safety: Percentage of BG less than 4.0mmol/L 
It is important to note that the figures for the number of BG measurements for the SING 
controller do not include those extra measurements taken hourly only for safety in planned 
clinical trials being designed. 
 
2.6 Virtual Patients 
The target patients for these trials are critically ill, but in a relatively stable state. Seventeen 
(of 391) patients from the SPRINT cohort [7] met the following stability criteria: 
• Stable hourly insulin requirement of ≤ 3U/hr of insulin, for at least 12 hours 
• Stable nutrition rate of ≥ 60% of the calculated individual patient’s goal rate, based on 
ACCP guidelines of 25kcal/kg/hr [24] 
• No acute renal failure 
• Less than 1000ml of fluid given as intravenous boluses in the past 24 hours, 
indicating hemodynamic or circulatory stability and a stable interstitial volume. 
• Resolving multiple organ failure based on a Sequential Organ Failure Assessment 
(SOFA) score < 6 [25] 
 
 
For safety and to limit Glargine bolus size in this initial study an additional criterion was: 
• Maximum total insulin requirement of ≤ 48U, over the last 18 hours 
These criteria define a set of patients who would be eligible for transfer to a HDU and a less 
intense AGC routine. The number (17) is low enough to create an initial protocol without 
excessive data, and other patients (of 391) might readily qualify. The total insulin dose 
criterion, chosen also for safety in planned clinical trials to limit dose, was a significant 
limiting factor for patient numbers. Table 3 presents the demographic details of the 17 
patients.  
 
Table 3: Patient Cohort 
Patient ID LOS (hrs) Medical Group Apache II score Age (years) Sex Mortality 
5006 161 Respiratory Failure 23 44 F N 
5033 100 Trauma 29 66 F N 
5054 158 Respiratory Failure 18 75 M N 
5060 271 Gastrointestinal 15 79 M N 
5061 140 Trauma 16 22 M N 
5076 240 Gastrointestinal 12 32 M N 
5086 127 Respiratory 32 64 M N 
5101 280 Neurological 19 50 F N 
5122 159 Trauma 19 73 M N 
5149 325 Surgical 21 60 M N 
5207 155 Respiratory 19 42 F N 
5279 85 Septic Shock 18 18 M N 
5299 103 Respiratory 20 56 F N 
5315 196 Respiratory 18 19 M N 
5322 136 Respiratory 15 72 F N 
5351 166 Respiratory 12 76 M N 
5376 120 Surgical 16 56 F N 
Median 158 
 
18 56 58% 
 IQR [127 - 196] 
 
[16 - 20] [42 - 72] Male 
 
3.0 Results 
Table 4 shows the expected glycemic differences between Glargine dose sizes for the 
nominal 1.5x efficacy. The sum over 18 hours was selected due to the safety limits imposed 
on the Glargine dosage, and it showed a balance of %BG within the 4.0 – 8.0 mmol/L band 
and %BG < 4.0 mmol/L, comparable to or better than SPRINT. While this choice reduced the 
number of nutrition changes required to maintain control using Glargine, it is evident that the 
fixed insulin dose requires greater nutrition adjustment compared to SPRINT, which used 
both in control. 
 
Table 4: Comparison of SING with dosage based on 12, 18 and 24 hours at 1.5x efficacy 
with STAR used for the first and last 4 hours 
  12 hour sum 18 hour sum 24 hour sum SPRINT 
BG measurements 258 260 266 267 
Boluses administered 112 113 112 311 
Nutrition changes 96 90 103 39 
% BG within 4.0 - 8.0 mmol/L 91.29 92.71 94.59 88.60 
Median glucose rate (%goal) 100% 100% 100% 90% 
% BG < 4.0 mmol/L 1.41 2.35 4.71 11.16 
Median Glargine Dose (U) [min max] 18.0 [6.0 - 30.0] 24.0 [6.0 - 48.0] 36.0 [6.0 - 72.0] N/A 
 
 
Table 5 shows a comparison at 1.5x efficacy for STAR running for the first and last 4 or 6 
hours of the 24 hours after Glargine is administered, as well as a comparison between if a 5th 
percentile or 95th percentile based targeting system is used. For a 4-hour STAR period (16h 
Glargine isolation) there was slightly poorer control compared to the 6-hour STAR period 
(12h Glargine isolation). However, the 4-hour STAR period still outperformed SPRINT and 
reduced mild hypoglycemia compared to the 6-hour STAR period. During the 16 hour 
Glargine isolation period there was a tendency for the controller to recommend lower 
nutrition rates for a 5th percentile BG outcome to low bound targeting system. Hence a 95th 
percentile BG outcome to high bound target was selected to meet clinical preferences for 
higher nutrition rates. 
 
Table 5: Comparison of SING with 5th percentile BG outcome to low bound and 95th 
percentile to high bound and 4 hour and 6 hour STAR periods at 1.5x efficacy 
  SPRINT 
4 hour STAR period, 
95th percentile to 
high bound 
6 hour STAR period, 
95th percentile to 
high bound 
4 hour STAR period, 
5th percentile to low 
bound 
BG measurements 267 260 307 257 
Boluses administered 311 113 167 111 
Nutrition changes 39 90 80 116 
% BG within 4.0 - 8.0 
mmol/L 88.60 92.71 94.59 95.06 
Median glucose rate 
(%goal) 90% 100% 100% 70% 
% BG < 4.0 mmol/L 11.16 2.35 4.00 3.06 
 
 
Based on these results, the final recommended SING controller comprises: 
• Glargine bolus size equal to the insulin administered over the previous 18 hours 
• STAR recommended boluses used for the first and last 4 hours of the 24 hour period 
after Glargine has been administered, 1 hour treatments only during this period. 
• During the period where Glargine is the only form of exogenous insulin, the 95th 
percentile BG outcome is targeted to the high bound, all other times the 5th percentile 
BG outcome is targeted to the low bound 
• The upper tolerance on the upper BG target is 1 mmol/L 
• Recommendations are made on the basis of a Glargine efficacy factor of 1.5 times 
• Recommended dosage is rounded to the nearest 6U for clinical convenience 
 
Table 6 shows the final SING controller compared against SPRINT with varying efficacy 
levels. Figure 5 shows how BG varies for a representative patient for the 24-hour trial after an 
initial Glargine dose of 18U. The varying efficacy and the relatively linear relation between 
BG and insulin efficiency is observed as expected. Safety was not compromised. 
Table 6: Final SING Controller 
  SPRINT SING 
Efficacy: - 1.0x 1.5x 2.0x 
BG measurements 267 269 260 254 
Boluses administered 311 114 113 110 
Nutrition changes 39 98 90 78 
% BG within 4.0 - 8.0 mmol/L 88.60 87.76 92.71 94.12 
Median glucose rate (% goal) 90% 100% 100% 100% 
% BG < 4.0 mmol/L 11.16 1.65 2.35 4.24 
 
 
Figure 5: Patient 5299 - Effects of Efficacy 
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The median nutrition rate is 100% of goal rate regardless of efficacy. The results show that 
adequate control is achieved for the case where Glargine is no more potent than regular 
insulin and control is improved for higher potencies of Glargine. However, for a higher 
potency, the risk of mild hypoglycemia increases, but even at the maximum suspected 
potency (2.0x) there is still a significant improvement over the SPRINT protocol. The 
cumulative frequency of BG levels in Figure 6 clearly shows robustness with a good balance 
of safety and performance. There is a significant reduction in %BG < 4.4 mmol/L, and the 
relatively steep CDF slopes indicate the BG variability remains tightly controlled. 
 
Figure 6: BG cumulative frequency for SING and SPRINT for all patients 
 
 
The controller has been shown to be robust with perturbations made to the initial Glargine 
bolus size, based on prior insulin requirements. The results from altering the length of time 
that Glargine bolus sizes are based on show that, at worst (1.0x efficacy based on insulin 
requirements over 12 hours), control within the target band is 84.0%. Safety is improved by 
using 1-hourly STAR treatments in conjunction with Glargine in the first and last 4-hours. 
0 5 10 15
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
BG [mmol/L]
C
um
ul
at
iv
e 
D
en
si
ty
 
 
Lo
w
er
 b
ou
nd
 (4
.4
 m
m
ol
/L
)
U
pp
er
 b
ou
nd
 (8
.0
 m
m
ol
/L
)
1.0 Efficacy
1.5 Efficacy
2.0 Efficacy
SPRINT
The tight control achieved by the hourly STAR treatments has been proven to effectively 
control BG levels. Any unknown effects of Glargine will be compensated for with the model 
calculated insulin sensitivity. The small variance between the bands for varying efficacies in 
Figure 6 further indicates the robustness.  
 
Table 7 shows an example the results from the SING2 controller, where it is assumed the 
efficacy is known to be 1.5. SING2 offers improved performance over SPRINT with 
increased nutrition delivery, patient safety, and time in desired band. A significant reduction 
in clinical effort is observed with a 27% reduction in BG measurements, a 59% reduction in 
insulin boluses and a 67% decrease in the number of nutrition changes required. Hence, if the 
efficacy is known reliably, then significant clinical effort reductions can be obtained with 
good performance and safety. 
Table 7: SING2 for known Efficacy 
  SPRINT SING2 Δ% 
BG measurements 267 196 -27% 
Boluses administered 311 129 -59% 
Nutrition changes 39 13 -67% 
% BG within 4.0 - 8.0 mmol/L 88.6 92.66 
+4.1% 
absolute 
Median glucose rate (% goal) 90% 100% 
+10% 
absolute 
% BG < 4.0 mmol/L 11.16 4.82 
-6.3% 
absolute 
 
  
4.0 Discussion: 
 
The simulation results for the SING controller and its variations show that it is a robust and 
safe initial protocol to investigate the safety and performance of Glargine in this cohort to 
reduce clinical effort and transition stable patients to subcutaneous delivery. A possible 
limitation of this study is the low number of virtual patients included in the cohort. SPRINT 
is used on a cohort from which such patients may come, but initial selection criteria may have 
been too strict. However, the cohort selected does fairly represent a combination of genders, 
medical conditions and age. A larger cohort of suitable patients, preferably in clinical testing, 
would enable a greater statistical validity of the results. However the results presented justify 
clinical testing to prove the concept. 
 
The unknown efficacy of Glargine requires specific measures to reduce patient risk in these 
trials. Hence, a noticeable decrease in clinical effort is not observed for SING in these 
proposed trials. Even though there is a significant reduction in insulin boluses administered 
there is a significant increase in the number of nutrition changes required. However, the 
SING2 controller showed the potential reductions available if the efficacy is more reliably 
known. Highly patient-specific or variable efficacy discovered in the clinical trials designed 
here would thus create significant issues affecting the feasibility of using Glargine 
consistently in large cohorts of this type if reduction of effort is a major criterion. 
 
In long term applications of Glargine over multiple days the periods of low insulin 
appearance in plasma during the Glargine’s action will not be an issue if the kinetics and 
efficacy of Glargine is known. A protocol can be designed such that the Glargine profiles 
overlap to minimise periods of low insulin appearance. This outcome is achieved by 
administering smaller doses more frequently than 24 hours. 
 
A limitation of this trial design is that the effect of Glargine build up over days is not 
observed. Build up can occur if Glargine is present for more than 24 hours [26]. Simulation 
results for a single isolated dose of Glargine suggested that the build up of Glargine in the 
interstitial insulin compartment was not a significant issue. However, this behaviour has been 
observed clinically and may still play a role. The increase in interstitial insulin concentration 
was 4.6% of the initial value after 24 hours and 2.5% after 26 hours. Hence, over several 
days, this issue may not be a major factor given measurement and other errors that also 
contribute to the overall variation in control. 
 
Finally, the goal of the controller was to investigate the kinetics and dynamics of Glargine. It 
is likely this information will be achieved through analysis of model-based SI as the patient 
transitions to/from the Glargine only period. If (for example) SI shows a general increase or 
decrease over the Glargine period that is resolved with the reintroduction of IV insulin it 
would infer values for Glargine potency. During the Glargine only period nutrition rates may 
be modified. 
  
5.0 Conclusions 
This paper presents an investigation into the use of Glargine in AGC for low effort 
controllers. A robust clinical trial has been designed to safely investigate the efficacy and 
kinetics of Glargine, prior to developing a final protocol. If the results of this trial verify the 
efficacy and kinetics of Glargine in critically ill patients, a low effort controller can be 
implemented to extend AGC to the HDU. It remains for clinical testing to determine inter- 
and intra- patient variability, thus determining the overall potential for using Glargine in large 
cohorts of HDU patients and stable ICU patients. 
Overall, the results demonstrate the concept and potential to justify pilot clinical trials. 
Equally they clearly and safely highlight, in-silico, some issues with subcutaneous long 
acting insulin that may not otherwise have arisen until clinical testing. Hence, these outcomes 
should be prospectively tested. 
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